Showing 5371-5380 of 9845 results for "".
- La Roche-Posay Unveils New Serum to Combat Dark Spotshttps://practicaldermatology.com/news/la-roche-posay-unveils-new-serum-combat-dark-spots/2462880/La Roche-Posay has announced the launch of its Mela B3 Dark Spot Serum & Mela B3 UV Daily Moisturizer SPF 30 products. Powered by Melasyl™, the manufacturer said in a news release, L'Oreal's multi-patented ingredient derived from 18 years of research, represents "a breakthrough in pig
- LEVEL UP: Upadacitinib Shows Superior Efficacy in ADhttps://practicaldermatology.com/news/level-study-upadacitinib-shows-superior-efficacy-ad/2462870/New topline results evaluating the efficacy and safety of upadacitinib for adults and adolescents with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable suggested that treatment with the drug was effective.<
- Study Shows Pediatric Skin Diseases Have Hidden Impact on Mental Healthhttps://practicaldermatology.com/news/study-shows-pediatric-skin-diseases-have-hidden-impact-mental-health/2462858/New research unveils the hidden impact on mental health that some chronic skin conditions take for pediatric patients. The cross-sectional study, published in JAMA Dermatology, was conducted across 32 pediatric dermatology centers in the United States and Canada and aimed to expl
- Abrocitinib Cost-Effective Compared to Standard of Care for Atopic Dermatitis Treatment: Studyhttps://practicaldermatology.com/news/abrocitinib-cost-effective-compared-standard-care-atopic-dermatitis-treatment-japan/2462838/New research from a study of Japanese patients suggests that abrocitinib showed superior efficacy and safety compared to the standard of care (SoC). Recent findings from the JAK-1 Atopic Dermatitis Efficacy and Safety (JADE) program's Phase 3 trials have unveiled promising insights into th
- UCB Receives European Approval for Hidradenitis Suppurativa Treatment Bimzelxhttps://practicaldermatology.com/news/ucb-receives-european-approval-hidradenitis-suppurativa-treatment-bimzelx/2462815/The European Commission has granted marketing authorization for UCB’s Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy.1 Bimzelx is the first IL-17A and IL-17F bi
- Oral and Topical Minoxidil for Male Androgenetic Alopecia Show Similar Efficacy: Analysishttps://practicaldermatology.com/news/oral-and-topical-minoxidil-male-androgenetic-alopecia-similar-efficacy-analysis/2462791/Low-dose oral minoxidil (5 mg once daily) was found to have similar effectiveness to topical minoxidil (5% twice per day) for the treatment of male androgenetic alopecia (AGA). The authors conducted the double-blind, placebo-controlled randomized clinical trial in Brazil aiming to evalua
- Study: Potential for Combined Laser Treating Vascular and Pigmented Lesionshttps://practicaldermatology.com/news/combined-laser-shows-potential-vascular-and-pigmented-lesions/2462743/A novel laser with cryogen cooling long-pulsed options of both 532nm and 1,064nm laser offers laser surgeons a safe and effective way to treat vascular and pigmented lesions with a single device and significantly different clinical endpoints, wrote Nicole M. Golbari, MD, of the University of Cali
- FDA Issues Alert for Counterfeit Botox Across Multiple U.S. Stateshttps://practicaldermatology.com/news/fda-issues-alert-counterfeit-botox-across-multiple-us-states/2462747/The U.S. Food and Drug Administration (FDA) has issued an alert regarding counterfeit botulinum toxin that has been detected in several states. The agency issued a statement on April 16 noting that it is aware of the issue and is working with the Centers for Disease Control (CDC), state
- Study: Fractional Laser and Botox Combo Shows Promise for Pore Reductionhttps://practicaldermatology.com/news/fractional-laser-and-botox-combination-shows-promise-pore-reduction/2462733/A single session of treatment with a fractional carbon dioxide laser followed by botulinum toxin type A was associated with significant reduction of facial pores in a pilot study presented at the American Society for Laser Medicine and Surgery (ASLMS) 43rd Annual Conference on Energy-b
- Study: Cryomodulation May Curb Acne Inflammationhttps://practicaldermatology.com/news/study-cryomodulation-may-curb-acne-inflammation/2462718/Cryomodulation was associated with significant inflammation reduction in patients with acne vulgaris, based on data from a new pilot study presented at the American Society for Laser Medicine and Surgery 43rd Annual Conference on Energy-based Medicine and Science in Baltimore.